NAD+ and NADH in Neuronal Death
- 268 Downloads
Neuronal death is a key pathological event in multiple neurological diseases. Increasing evidence has suggested that NAD+ and NADH mediate not only energy metabolism and mitochondrial functions, but also calcium homeostasis, aging, and cell death. This article is written to provide an overview about the information suggesting significant roles of NAD+ and NADH in neuronal death in certain neurological diseases. Our latest studies have suggested that intranasal administration with NAD+ can profoundly decrease ischemic brain damage. These observations suggest that NAD+ administration may be a novel therapeutic strategy for some neurological diseases.
KeywordsNAD+ NADH neuronal death brain injury cerebral ischemia neurodegenerative diseases
The author would like to acknowledge the grant support from NIH, VA, and AHA. The author would also like to thank the work of the current and previous members of his laboratory, including Dr. Guangwei Wei, Dr. Huafei Lu, Dr. Peng Zhang, and Mrs. Dongming Wang.
- Blenn C, Althaus FR, Malanga M (2006) Poly(ADP-ribose) glycohydrolase silencing protects against H2O2-induced cell death. Biochem J 396:419–429Google Scholar
- Boulares AH, Zoltoski AJ, Sherif ZA, Yakovlev AG, Smulson ME (2002) The poly(ADP-ribose) polymerase-1-regulated endonuclease DNAS1L3 is required for etoposide-induced internucleosomal DNA fragmentation and increases etoposide cytotoxicity in transfected osteosarcoma cells. Cancer Res 62:4439–4444PubMedGoogle Scholar
- Burns D, Ying W, Garnier P, Swanson RA (2004) Decreases expression of the full-length poly(ADP-ribose) glycohydrolase by antisense oligonucleotide treatment prevents PARP-1-mediated astrocyte death. 2004 American Society for Neurosciences Annual Meeting Abstracts.Google Scholar
- Diestel A, Aktas O, Hackel D, Hake I, Meier S, Raine CS, Nitsch R, Zipp F, Ullrich O (2003) Activation of microglial poly(ADP-ribose)-polymerase-1 by cholesterol breakdown products during neuroinflammation: a link between demyelination and neuronal damage. J Exp Med 198:1729–1740PubMedCrossRefGoogle Scholar
- Hensley K, Butterfield DA, Hall N, Cole P, Subramaniam R, Mark R, Mattson MP, Markesbery WR, Harris ME, Aksenov M et al. (1996) Reactive oxygen species as causal agents in the neurotoxicity of the Alzheimer’s disease-associated amyloid beta peptide. Ann N Y Acad Sci 786:120–134PubMedCrossRefGoogle Scholar
- Iwashita A, Yamazaki S, Mihara K, Hattori K, Yamamoto H, Ishida J, Matsuoka N, Mutoh S (2004) Neuroprotective effects of a novel poly(ADP-ribose) polymerase-1 inhibitor, 2-[3-[4-(4-chlorophenyl)-1-piperazinyl] propyl]-4(3H)-quinazolinone (FR255595), in an in vitro model of cell death and in mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson’s disease. J Pharmacol Exp Ther 309:1067–1078PubMedCrossRefGoogle Scholar
- Mandir AS, Przedborski S, Jackson-Lewis V, Wang ZQ, Simbulan-Rosenthal CM, Smulson ME, Hoffman BE, Guastella DB, Dawson VL, Dawson TM (1999) Poly(ADP-ribose) polymerase activation mediates 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism. Proc Natl Acad Sci U S A 96:5774–5779PubMedCrossRefGoogle Scholar
- Wei G, Wang D, Zhang P, Ying W (2006) Intranasal delivery of gallotannin decreases ischemic brain damage in a rat model of transient focal ischemia with extended window of opportunity. 2006. 36th American Society for Neurosciences Annual Meeting AbstractsGoogle Scholar